RTN4 and myeloid sarcoma: In comparison to this control group, the CNS sample from the DMF‐treated MS patient revealed a lower number of acutely damaged axons, along with a comparably high number of Nogo‐A+ mature oligodendrocytes (Figure 7A,B).